Header Logo

Connection

Jeremy Luban to Virus Replication

This is a "connection" page, showing publications Jeremy Luban has written about Virus Replication.
Connection Strength

4.524
  1. Luban J, Sattler RA, M?hlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, Pykett M, Welch EM, O'Keefe K, Kong R, Goodwin E, Jacobson A, Paessler S, Peltz SW. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Res. 2021 01 15; 292:198246.
    View in: PubMed
    Score: 0.639
  2. Kim K, Dauphin A, Komurlu S, McCauley SM, Yurkovetskiy L, Carbone C, Diehl WE, Strambio-De-Castillia C, Campbell EM, Luban J. Cyclophilin A protects HIV-1 from restriction by human TRIM5a. Nat Microbiol. 2019 12; 4(12):2044-2051.
    View in: PubMed
    Score: 0.592
  3. McCauley SM, Kim K, Nowosielska A, Dauphin A, Yurkovetskiy L, Diehl WE, Luban J. Intron-containing RNA from the HIV-1 provirus activates type I interferon and inflammatory cytokines. Nat Commun. 2018 12 13; 9(1):5305.
    View in: PubMed
    Score: 0.558
  4. De Iaco A, Santoni F, Vannier A, Guipponi M, Antonarakis S, Luban J. TNPO3 protects HIV-1 replication from CPSF6-mediated capsid stabilization in the host cell cytoplasm. Retrovirology. 2013 Feb 15; 10:20.
    View in: PubMed
    Score: 0.373
  5. Luban J. HIV-1 infection: going nuclear with TNPO3/Transportin-SR2 and integrase. Curr Biol. 2008 Aug 26; 18(16):R710-3.
    View in: PubMed
    Score: 0.273
  6. Sokolskaja E, Sayah DM, Luban J. Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. J Virol. 2004 Dec; 78(23):12800-8.
    View in: PubMed
    Score: 0.211
  7. Berthoux L, Sebastian S, Sokolskaja E, Luban J. Lv1 inhibition of human immunodeficiency virus type 1 is counteracted by factors that stimulate synthesis or nuclear translocation of viral cDNA. J Virol. 2004 Nov; 78(21):11739-50.
    View in: PubMed
    Score: 0.210
  8. Chiramel AI, Meyerson NR, McNally KL, Broeckel RM, Montoya VR, M?ndez-Sol?s O, Robertson SJ, Sturdevant GL, Lubick KJ, Nair V, Youseff BH, Ireland RM, Bosio CM, Kim K, Luban J, Hirsch VM, Taylor RT, Bouamr F, Sawyer SL, Best SM. TRIM5a Restricts Flavivirus Replication by Targeting the Viral Protease for Proteasomal Degradation. Cell Rep. 2019 06 11; 27(11):3269-3283.e6.
    View in: PubMed
    Score: 0.144
  9. Yin L, Braaten D, Luban J. Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol. 1998 Aug; 72(8):6430-6.
    View in: PubMed
    Score: 0.136
  10. Braaten D, Franke EK, Luban J. Cyclophilin A is required for the replication of group M human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus SIV(CPZ)GAB but not group O HIV-1 or other primate immunodeficiency viruses. J Virol. 1996 Jul; 70(7):4220-7.
    View in: PubMed
    Score: 0.118
  11. Franke EK, Luban J. Cyclophilin and gag in HIV-1 replication and pathogenesis. Adv Exp Med Biol. 1995; 374:217-28.
    View in: PubMed
    Score: 0.106
  12. De Iaco A, Luban J. Inhibition of HIV-1 infection by TNPO3 depletion is determined by capsid and detectable after viral cDNA enters the nucleus. Retrovirology. 2011 Dec 06; 8:98.
    View in: PubMed
    Score: 0.086
  13. Kajaste-Rudnitski A, Marelli SS, Pultrone C, Pertel T, Uchil PD, Mechti N, Mothes W, Poli G, Luban J, Vicenzi E. TRIM22 inhibits HIV-1 transcription independently of its E3 ubiquitin ligase activity, Tat, and NF-kappaB-responsive long terminal repeat elements. J Virol. 2011 May; 85(10):5183-96.
    View in: PubMed
    Score: 0.081
  14. Strebel K, Luban J, Jeang KT. Human cellular restriction factors that target HIV-1 replication. BMC Med. 2009 Sep 16; 7:48.
    View in: PubMed
    Score: 0.074
  15. Kaul A, Stauffer S, Berger C, Pertel T, Schmitt J, Kallis S, Zayas M, Lopez MZ, Lohmann V, Luban J, Bartenschlager R. Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics. PLoS Pathog. 2009 Aug; 5(8):e1000546.
    View in: PubMed
    Score: 0.073
  16. Berthoux L, Sebastian S, Muesing MA, Luban J. The role of lysine 186 in HIV-1 integrase multimerization. Virology. 2007 Jul 20; 364(1):227-36.
    View in: PubMed
    Score: 0.062
  17. Sokolskaja E, Luban J. Cyclophilin, TRIM5, and innate immunity to HIV-1. Curr Opin Microbiol. 2006 Aug; 9(4):404-8.
    View in: PubMed
    Score: 0.059
  18. Sokolskaja E, Berthoux L, Luban J. Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. J Virol. 2006 Mar; 80(6):2855-62.
    View in: PubMed
    Score: 0.058
  19. Gurer C, Berthoux L, Luban J. Covalent modification of human immunodeficiency virus type 1 p6 by SUMO-1. J Virol. 2005 Jan; 79(2):910-7.
    View in: PubMed
    Score: 0.053
  20. Padron A, Dwivedi R, Chakraborty R, Prakash P, Kim K, Shi J, Ahn J, Pandhare J, Luban J, Aiken C, Balasubramaniam M, Dash C. Cyclophilin A facilitates HIV-1 integration. J Virol. 2024 Nov 19; 98(11):e0094724.
    View in: PubMed
    Score: 0.052
  21. Berthoux L, Towers GJ, Gurer C, Salomoni P, Pandolfi PP, Luban J. As(2)O(3) enhances retroviral reverse transcription and counteracts Ref1 antiviral activity. J Virol. 2003 Mar; 77(5):3167-80.
    View in: PubMed
    Score: 0.047
  22. Braaten D, Luban J. Cyclophilin A regulates HIV-1 infectivity, as demonstrated by gene targeting in human T cells. EMBO J. 2001 Mar 15; 20(6):1300-9.
    View in: PubMed
    Score: 0.041
  23. Cimarelli A, Luban J. Human immunodeficiency virus type 1 virion density is not determined by nucleocapsid basic residues. J Virol. 2000 Aug; 74(15):6734-40.
    View in: PubMed
    Score: 0.039
  24. Cimarelli A, Sandin S, H?glund S, Luban J. Rescue of multiple viral functions by a second-site suppressor of a human immunodeficiency virus type 1 nucleocapsid mutation. J Virol. 2000 May; 74(9):4273-83.
    View in: PubMed
    Score: 0.038
  25. Cimarelli A, Sandin S, H?glund S, Luban J. Basic residues in human immunodeficiency virus type 1 nucleocapsid promote virion assembly via interaction with RNA. J Virol. 2000 Apr; 74(7):3046-57.
    View in: PubMed
    Score: 0.038
  26. Burniston MT, Cimarelli A, Colgan J, Curtis SP, Luban J. Human immunodeficiency virus type 1 Gag polyprotein multimerization requires the nucleocapsid domain and RNA and is promoted by the capsid-dimer interface and the basic region of matrix protein. J Virol. 1999 Oct; 73(10):8527-40.
    View in: PubMed
    Score: 0.037
  27. Cimarelli A, Luban J. Translation elongation factor 1-alpha interacts specifically with the human immunodeficiency virus type 1 Gag polyprotein. J Virol. 1999 Jul; 73(7):5388-401.
    View in: PubMed
    Score: 0.036
  28. Yin L, Boussard S, Allan J, Luban J. The HIV type 1 replication block in nonhuman primates is not explained by differences in cyclophilin A primary structure. AIDS Res Hum Retroviruses. 1998 Jan 01; 14(1):95-7.
    View in: PubMed
    Score: 0.033
  29. Re F, Luban J. HIV-1 Vpr: G2 cell cycle arrest, macrophages and nuclear transport. Prog Cell Cycle Res. 1997; 3:21-7.
    View in: PubMed
    Score: 0.030
  30. Luban J. Absconding with the chaperone: essential cyclophilin-Gag interaction in HIV-1 virions. Cell. 1996 Dec 27; 87(7):1157-9.
    View in: PubMed
    Score: 0.030
  31. Franke EK, Luban J. Inhibition of HIV-1 replication by cyclosporine A or related compounds correlates with the ability to disrupt the Gag-cyclophilin A interaction. Virology. 1996 Aug 01; 222(1):279-82.
    View in: PubMed
    Score: 0.030
  32. Braaten D, Franke EK, Luban J. Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription. J Virol. 1996 Jun; 70(6):3551-60.
    View in: PubMed
    Score: 0.029
  33. Franke EK, Yuan HE, Luban J. Specific incorporation of cyclophilin A into HIV-1 virions. Nature. 1994 Nov 24; 372(6504):359-62.
    View in: PubMed
    Score: 0.026
  34. Singh R, Patel V, Mureithi MW, Naranbhai V, Ramsuran D, Tulsi S, Hiramen K, Werner L, Mlisana K, Altfeld M, Luban J, Kasprowicz V, Dheda K, Abdool Karim SS, Ndung'u T. TRIM5a and TRIM22 are differentially regulated according to HIV-1 infection phase and compartment. J Virol. 2014 Apr; 88(8):4291-303.
    View in: PubMed
    Score: 0.025
  35. Yang Y, Luban J, Diaz-Griffero F. The fate of HIV-1 capsid: a biochemical assay for HIV-1 uncoating. Methods Mol Biol. 2014; 1087:29-36.
    View in: PubMed
    Score: 0.025
  36. Lai RP, Yan J, Heeney J, McClure MO, G?ttlinger H, Luban J, Pizzato M. Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog. 2011 Dec; 7(12):e1002442.
    View in: PubMed
    Score: 0.021
  37. Goujon C, Arfi V, Pertel T, Luban J, Lienard J, Rigal D, Darlix JL, Cimarelli A. Characterization of simian immunodeficiency virus SIVSM/human immunodeficiency virus type 2 Vpx function in human myeloid cells. J Virol. 2008 Dec; 82(24):12335-45.
    View in: PubMed
    Score: 0.017
  38. Takeuchi H, Buckler-White A, Goila-Gaur R, Miyagi E, Khan MA, Opi S, Kao S, Sokolskaja E, Pertel T, Luban J, Strebel K. Vif counteracts a cyclophilin A-imposed inhibition of simian immunodeficiency viruses in human cells. J Virol. 2007 Aug; 81(15):8080-90.
    View in: PubMed
    Score: 0.016
  39. Dorfman T, Luban J, Goff SP, Haseltine WA, G?ttlinger HG. Mapping of functionally important residues of a cysteine-histidine box in the human immunodeficiency virus type 1 nucleocapsid protein. J Virol. 1993 Oct; 67(10):6159-69.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.